GSK’s Vallance On Efficiency In R&D And Entering “The Cure” Era
Executive Summary
Dr Patrick Vallance, President R&D at GlaxoSmithKline, tells Scrip that R&D efficiency is a priority for the company and specifies increased transparency on R&D decision-making and its returns. In a wide-ranging interview, Vallance also discusses the attention GSK’s Nucala is garnering within the severe asthma space.